Abstract
Psoriasis is a common, chronic, inflammatory, multisystem disease with predominantly skin and joint manifestations affecting approximately 2% of the population. In this first of 5 sections of the guidelines of care for psoriasis, we discuss the classification of psoriasis; associated comorbidities including autoimmune diseases, cardiovascular risk, psychiatric/psychologic issues, and cancer risk; along with assessment tools for skin disease and quality-of-life issues. Finally, we will discuss the safety and efficacy of the biologic treatments used to treat patients with psoriasis.
Publication types
-
Consensus Development Conference
-
Practice Guideline
MeSH terms
-
Acitretin / adverse effects
-
Alefacept
-
Antibodies, Monoclonal / therapeutic use
-
Antibodies, Monoclonal, Humanized
-
Arthritis, Psoriatic / drug therapy*
-
Biological Products / therapeutic use*
-
Cardiovascular Diseases / etiology
-
Cyclosporine / therapeutic use
-
Depression / etiology
-
Etanercept
-
Humans
-
Immunoglobulin G / adverse effects
-
Interleukin-12 / antagonists & inhibitors
-
Interleukin-23 / antagonists & inhibitors
-
Lymphoma / etiology
-
Metabolic Syndrome / complications
-
Methotrexate / adverse effects
-
Obesity / complications
-
PUVA Therapy
-
Psoriasis / complications
-
Psoriasis / drug therapy*
-
Receptors, Tumor Necrosis Factor
-
Recombinant Fusion Proteins / therapeutic use
-
Smoking / adverse effects
-
Tumor Necrosis Factor-alpha / antagonists & inhibitors
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Biological Products
-
Immunoglobulin G
-
Interleukin-23
-
Receptors, Tumor Necrosis Factor
-
Recombinant Fusion Proteins
-
Tumor Necrosis Factor-alpha
-
Interleukin-12
-
Cyclosporine
-
Alefacept
-
Acitretin
-
Etanercept
-
efalizumab
-
Methotrexate